PMC:7074424 / 28495-29205 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"665","span":{"begin":120,"end":129},"obj":"Species"},{"id":"666","span":{"begin":266,"end":275},"obj":"Chemical"},{"id":"667","span":{"begin":277,"end":288},"obj":"Chemical"},{"id":"668","span":{"begin":290,"end":300},"obj":"Chemical"},{"id":"669","span":{"begin":302,"end":333},"obj":"Chemical"},{"id":"670","span":{"begin":335,"end":346},"obj":"Chemical"},{"id":"671","span":{"begin":348,"end":360},"obj":"Chemical"},{"id":"672","span":{"begin":362,"end":373},"obj":"Chemical"},{"id":"673","span":{"begin":377,"end":395},"obj":"Chemical"},{"id":"674","span":{"begin":397,"end":411},"obj":"Chemical"},{"id":"675","span":{"begin":413,"end":432},"obj":"Chemical"},{"id":"676","span":{"begin":437,"end":444},"obj":"Chemical"},{"id":"677","span":{"begin":446,"end":456},"obj":"Chemical"},{"id":"678","span":{"begin":548,"end":557},"obj":"Chemical"},{"id":"679","span":{"begin":134,"end":142},"obj":"Disease"}],"attributes":[{"id":"A665","pred":"tao:has_database_id","subj":"665","obj":"Tax:2697049"},{"id":"A666","pred":"tao:has_database_id","subj":"666","obj":"MESH:D001205"},{"id":"A667","pred":"tao:has_database_id","subj":"667","obj":"MESH:C462182"},{"id":"A668","pred":"tao:has_database_id","subj":"668","obj":"MESH:D000068879"},{"id":"A670","pred":"tao:has_database_id","subj":"670","obj":"MESH:D000077339"},{"id":"A671","pred":"tao:has_database_id","subj":"671","obj":"MESH:D004176"},{"id":"A672","pred":"tao:has_database_id","subj":"672","obj":"MESH:D002738"},{"id":"A673","pred":"tao:has_database_id","subj":"673","obj":"MESH:D006886"},{"id":"A674","pred":"tao:has_database_id","subj":"674","obj":"MESH:D013498"},{"id":"A675","pred":"tao:has_database_id","subj":"675","obj":"MESH:C558899"},{"id":"A676","pred":"tao:has_database_id","subj":"676","obj":"MESH:C086979"},{"id":"A677","pred":"tao:has_database_id","subj":"677","obj":"MESH:C086979"},{"id":"A679","pred":"tao:has_database_id","subj":"679","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"A total of 233 trials are registered till date in the Chinese Clinical Trial Registry[94] (dated Feb 24, 2020, keywords 2019-nCov and COVID-19). Among the pharmacotherapeutic agents evaluated, some of the highlighted agents, which are being evaluated, are high-dose Vitamin C, favipiravir, adalimumab, dihydro-artemisinin piperaquine, leflunomide, dipyridamole, chloroquine or hydroxychloroquine, suramin sodium, lopinavir/ritonavir and arbidol (umifenovir) tablets, and IFN-alpha 2b. Other important agents being evaluated are Huo-Shen particles, Xiyanping injection, Shen-Fu injection, etc., many of which are from traditional Chinese medicines background. Use of stem cells is also evaluated frequently.[94]"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T912","span":{"begin":120,"end":129},"obj":"SP_7"},{"id":"T911","span":{"begin":134,"end":142},"obj":"SP_7"},{"id":"T910","span":{"begin":155,"end":181},"obj":"CHEBI:52217;CHEBI:52217"},{"id":"T909","span":{"begin":266,"end":275},"obj":"CHEBI:21241;CHEBI:21241"},{"id":"T907","span":{"begin":290,"end":300},"obj":"CHEBI:28748;CHEBI:28748;DG_1"},{"id":"T906","span":{"begin":302,"end":309},"obj":"CHEBI:50488;CHEBI:50488"},{"id":"T905","span":{"begin":322,"end":333},"obj":"CHEBI:17939;CHEBI:17939"},{"id":"T904","span":{"begin":335,"end":346},"obj":"CHEBI:6402;CHEBI:6402"},{"id":"T903","span":{"begin":348,"end":360},"obj":"CHEBI:4653;CHEBI:4653"},{"id":"T902","span":{"begin":362,"end":373},"obj":"CHEBI:3638;CHEBI:3638;DG_10"},{"id":"T901","span":{"begin":377,"end":395},"obj":"CHEBI:5801;CHEBI:5801;DG_20"},{"id":"T900","span":{"begin":413,"end":422},"obj":"DG_23"},{"id":"T899","span":{"begin":423,"end":432},"obj":"DG_30"},{"id":"T898","span":{"begin":437,"end":444},"obj":"DG_49"},{"id":"T897","span":{"begin":446,"end":456},"obj":"DG_49"},{"id":"T896","span":{"begin":471,"end":483},"obj":"PR:000008915"},{"id":"T895","span":{"begin":666,"end":676},"obj":"CL:0000034"},{"id":"T908","span":{"begin":277,"end":288},"obj":"CHEBI:119915;CHEBI:119915;DG_17;NCBITaxon:31032"}],"text":"A total of 233 trials are registered till date in the Chinese Clinical Trial Registry[94] (dated Feb 24, 2020, keywords 2019-nCov and COVID-19). Among the pharmacotherapeutic agents evaluated, some of the highlighted agents, which are being evaluated, are high-dose Vitamin C, favipiravir, adalimumab, dihydro-artemisinin piperaquine, leflunomide, dipyridamole, chloroquine or hydroxychloroquine, suramin sodium, lopinavir/ritonavir and arbidol (umifenovir) tablets, and IFN-alpha 2b. Other important agents being evaluated are Huo-Shen particles, Xiyanping injection, Shen-Fu injection, etc., many of which are from traditional Chinese medicines background. Use of stem cells is also evaluated frequently.[94]"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T270","span":{"begin":666,"end":676},"obj":"Body_part"},{"id":"T271","span":{"begin":671,"end":676},"obj":"Body_part"}],"attributes":[{"id":"A270","pred":"fma_id","subj":"T270","obj":"http://purl.org/sig/ont/fma/fma63368"},{"id":"A271","pred":"fma_id","subj":"T271","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"A total of 233 trials are registered till date in the Chinese Clinical Trial Registry[94] (dated Feb 24, 2020, keywords 2019-nCov and COVID-19). Among the pharmacotherapeutic agents evaluated, some of the highlighted agents, which are being evaluated, are high-dose Vitamin C, favipiravir, adalimumab, dihydro-artemisinin piperaquine, leflunomide, dipyridamole, chloroquine or hydroxychloroquine, suramin sodium, lopinavir/ritonavir and arbidol (umifenovir) tablets, and IFN-alpha 2b. Other important agents being evaluated are Huo-Shen particles, Xiyanping injection, Shen-Fu injection, etc., many of which are from traditional Chinese medicines background. Use of stem cells is also evaluated frequently.[94]"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T133","span":{"begin":134,"end":142},"obj":"Disease"}],"attributes":[{"id":"A133","pred":"mondo_id","subj":"T133","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"A total of 233 trials are registered till date in the Chinese Clinical Trial Registry[94] (dated Feb 24, 2020, keywords 2019-nCov and COVID-19). Among the pharmacotherapeutic agents evaluated, some of the highlighted agents, which are being evaluated, are high-dose Vitamin C, favipiravir, adalimumab, dihydro-artemisinin piperaquine, leflunomide, dipyridamole, chloroquine or hydroxychloroquine, suramin sodium, lopinavir/ritonavir and arbidol (umifenovir) tablets, and IFN-alpha 2b. Other important agents being evaluated are Huo-Shen particles, Xiyanping injection, Shen-Fu injection, etc., many of which are from traditional Chinese medicines background. Use of stem cells is also evaluated frequently.[94]"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T280","span":{"begin":0,"end":1},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T281","span":{"begin":86,"end":88},"obj":"http://purl.obolibrary.org/obo/CLO_0001527"},{"id":"T282","span":{"begin":666,"end":676},"obj":"http://purl.obolibrary.org/obo/CL_0000034"},{"id":"T283","span":{"begin":707,"end":709},"obj":"http://purl.obolibrary.org/obo/CLO_0001527"}],"text":"A total of 233 trials are registered till date in the Chinese Clinical Trial Registry[94] (dated Feb 24, 2020, keywords 2019-nCov and COVID-19). Among the pharmacotherapeutic agents evaluated, some of the highlighted agents, which are being evaluated, are high-dose Vitamin C, favipiravir, adalimumab, dihydro-artemisinin piperaquine, leflunomide, dipyridamole, chloroquine or hydroxychloroquine, suramin sodium, lopinavir/ritonavir and arbidol (umifenovir) tablets, and IFN-alpha 2b. Other important agents being evaluated are Huo-Shen particles, Xiyanping injection, Shen-Fu injection, etc., many of which are from traditional Chinese medicines background. Use of stem cells is also evaluated frequently.[94]"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T361","span":{"begin":266,"end":275},"obj":"Chemical"},{"id":"T364","span":{"begin":266,"end":273},"obj":"Chemical"},{"id":"T365","span":{"begin":277,"end":288},"obj":"Chemical"},{"id":"T366","span":{"begin":302,"end":321},"obj":"Chemical"},{"id":"T368","span":{"begin":310,"end":321},"obj":"Chemical"},{"id":"T369","span":{"begin":322,"end":333},"obj":"Chemical"},{"id":"T370","span":{"begin":335,"end":346},"obj":"Chemical"},{"id":"T371","span":{"begin":348,"end":360},"obj":"Chemical"},{"id":"T372","span":{"begin":362,"end":373},"obj":"Chemical"},{"id":"T373","span":{"begin":377,"end":395},"obj":"Chemical"},{"id":"T374","span":{"begin":397,"end":404},"obj":"Chemical"},{"id":"T375","span":{"begin":405,"end":411},"obj":"Chemical"},{"id":"T376","span":{"begin":413,"end":432},"obj":"Chemical"},{"id":"T377","span":{"begin":413,"end":422},"obj":"Chemical"},{"id":"T378","span":{"begin":423,"end":432},"obj":"Chemical"},{"id":"T379","span":{"begin":437,"end":444},"obj":"Chemical"},{"id":"T380","span":{"begin":446,"end":456},"obj":"Chemical"},{"id":"T381","span":{"begin":471,"end":474},"obj":"Chemical"},{"id":"T382","span":{"begin":475,"end":480},"obj":"Chemical"}],"attributes":[{"id":"A361","pred":"chebi_id","subj":"T361","obj":"http://purl.obolibrary.org/obo/CHEBI_21241"},{"id":"A362","pred":"chebi_id","subj":"T361","obj":"http://purl.obolibrary.org/obo/CHEBI_29073"},{"id":"A363","pred":"chebi_id","subj":"T361","obj":"http://purl.obolibrary.org/obo/CHEBI_38290"},{"id":"A364","pred":"chebi_id","subj":"T364","obj":"http://purl.obolibrary.org/obo/CHEBI_33229"},{"id":"A365","pred":"chebi_id","subj":"T365","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A366","pred":"chebi_id","subj":"T366","obj":"http://purl.obolibrary.org/obo/CHEBI_135921"},{"id":"A367","pred":"chebi_id","subj":"T366","obj":"http://purl.obolibrary.org/obo/CHEBI_207229"},{"id":"A368","pred":"chebi_id","subj":"T368","obj":"http://purl.obolibrary.org/obo/CHEBI_223316"},{"id":"A369","pred":"chebi_id","subj":"T369","obj":"http://purl.obolibrary.org/obo/CHEBI_91231"},{"id":"A370","pred":"chebi_id","subj":"T370","obj":"http://purl.obolibrary.org/obo/CHEBI_6402"},{"id":"A371","pred":"chebi_id","subj":"T371","obj":"http://purl.obolibrary.org/obo/CHEBI_4653"},{"id":"A372","pred":"chebi_id","subj":"T372","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A373","pred":"chebi_id","subj":"T373","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A374","pred":"chebi_id","subj":"T374","obj":"http://purl.obolibrary.org/obo/CHEBI_45906"},{"id":"A375","pred":"chebi_id","subj":"T375","obj":"http://purl.obolibrary.org/obo/CHEBI_26708"},{"id":"A376","pred":"chebi_id","subj":"T376","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A377","pred":"chebi_id","subj":"T377","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A378","pred":"chebi_id","subj":"T378","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A379","pred":"chebi_id","subj":"T379","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A380","pred":"chebi_id","subj":"T380","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A381","pred":"chebi_id","subj":"T381","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A382","pred":"chebi_id","subj":"T382","obj":"http://purl.obolibrary.org/obo/CHEBI_30216"}],"text":"A total of 233 trials are registered till date in the Chinese Clinical Trial Registry[94] (dated Feb 24, 2020, keywords 2019-nCov and COVID-19). Among the pharmacotherapeutic agents evaluated, some of the highlighted agents, which are being evaluated, are high-dose Vitamin C, favipiravir, adalimumab, dihydro-artemisinin piperaquine, leflunomide, dipyridamole, chloroquine or hydroxychloroquine, suramin sodium, lopinavir/ritonavir and arbidol (umifenovir) tablets, and IFN-alpha 2b. Other important agents being evaluated are Huo-Shen particles, Xiyanping injection, Shen-Fu injection, etc., many of which are from traditional Chinese medicines background. Use of stem cells is also evaluated frequently.[94]"}

{"project":"LitCovid-sentences","denotations":[{"id":"T174","span":{"begin":0,"end":144},"obj":"Sentence"},{"id":"T175","span":{"begin":145,"end":484},"obj":"Sentence"},{"id":"T176","span":{"begin":485,"end":658},"obj":"Sentence"},{"id":"T177","span":{"begin":659,"end":710},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"A total of 233 trials are registered till date in the Chinese Clinical Trial Registry[94] (dated Feb 24, 2020, keywords 2019-nCov and COVID-19). Among the pharmacotherapeutic agents evaluated, some of the highlighted agents, which are being evaluated, are high-dose Vitamin C, favipiravir, adalimumab, dihydro-artemisinin piperaquine, leflunomide, dipyridamole, chloroquine or hydroxychloroquine, suramin sodium, lopinavir/ritonavir and arbidol (umifenovir) tablets, and IFN-alpha 2b. Other important agents being evaluated are Huo-Shen particles, Xiyanping injection, Shen-Fu injection, etc., many of which are from traditional Chinese medicines background. Use of stem cells is also evaluated frequently.[94]"}